<DOC>
	<DOCNO>NCT00293462</DOCNO>
	<brief_summary>RATIONALE : GM-CSF may protect normal cell side effect , mucositis , radiation therapy may help damage tissue heal faster radiation therapy . PURPOSE : This randomized clinical trial study well GM-CSF work prevent treat mucositis patient undergo radiation therapy head neck cancer .</brief_summary>
	<brief_title>GM-CSF Mouthwash Preventing Treating Mucositis Patients Who Are Undergoing Radiation Therapy Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence radiotherapy ( RT ) -induced oral mucositis grade , use Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria ( RTOG ARMSC ) -Mucous Membrane , patient treat 1 2 mouthwash ( sargramostim [ GM-CSF ] salt soda ) . ( prevention portion study ) - Compare effectiveness 2 mouthwash treat oral mucositis define incidence RTOG ARMSC-Mucous Membrane grade 3 4 mucositis patient 1 3 group ( salt soda , continue GM-CSF , new GM-CSF ) . ( treatment portion study ) Secondary - Compare effectiveness 2 mouthwash prevent RT-induced oral mucositis follow direct index : - Cumulative RT dose prior onset oral mucositis ( prevention portion ) - Severity RT-induced oral mucositis onset treatment ( use Oral Mucositis Assessment Scale [ OMAS ] ) - Severity oral mucositis-related pain onset treatment ( use OMAS ) - Incidence oral mucositis-related infection onset treatment ( use OMAS ) - Severity oral mucositis-related problem ingestion food fluid onset treatment ( use OMAS ) - Time heal RT-induced oral mucositis . - Evaluate patient use follow indirect index oral mucositis morbidity prevention treatment portion study . - Tolerance RT regimen - Functional status - Quality life . OUTLINE : This multicenter , randomize , control , double-blinded study . Patients stratify accord radiotherapy dose schedule ( standard v hyperfractionation v intensity modulation ) concurrent chemotherapy ( yes v ) . - Prevention ( mucositis ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sargramostim ( GM-CSF ) mouthwash , hold mouth swallow interval 1 hour daily . - Arm II : Patients receive oral salt soda mouthwash , hold swallow interval 1 hour daily . Treatment arm continue 6-7 week radiotherapy and/or onset mucositis . Patients also perform PRO-SELF : Mouth Aware ( PSMA ) twice daily . - Treatment ( onset mucositis ) : Patients currently use GM-CSF mouthwash continue use prevention . Patients currently use salt soda mouthwash randomize 1 2 treatment arm . - Arm III : Patients receive GM-CSF mouthwash arm I . - Arm IV : Patients receive salt soda mouthwash arm II . In arm , treatment continue mucositis heals . Patients perform PSMA four time daily 3 month radiotherapy . Quality life assess baseline periodically radiotherapy . After completion study treatment , patient follow every month 3 month . PROJECTED ACCRUAL : A total 222 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm diagnosis head neck cancer Scheduled undergo continuous course conventional hyperfractionated radiotherapy intensitymodulated radiotherapy ( IMRT ) without concurrent chemotherapy Planning receive total radiation dose ≥ 5,500 cGy , administer single daily fraction 180220 cGy ( 5 day week ) twice daily fraction 110150 cGy Normal baseline oral examination ( preexist lesion ) No T1 T2 glottic tumor PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Mentally capable participate research protocol Expected survival &gt; 4.5 month No serious concurrent medical illness Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2.0 mg/dL AST &lt; 5 time upper limit normal HIV negative No history insulindependent diabetes mellitus No prior hypersensitivity reaction yeast material No recent history oral ulceration , herpes simplex , oral candidiasis , severe gingivitis , active chronic mucositis , xerostomia No current New York Heart Association class IIIV congestive heart failure Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No unresolved adverse event previous therapy No prior radiotherapy head neck No prior concurrent brachytherapy No prior participation study No chemotherapy , radiotherapy , investigational drug within past 4 week No major surgery within past 2 week No systemic sargramostim ( GMCSF ) within past 7 day No systemic filgrastim ( GCSF ) within past 24 hour No systemic longacting pegfilgrastim within past 14 day No antibiotic , antifungal , antiviral oral condition baseline No concurrent chemotherapy agent No concurrent enrollment head neck study No concurrent investigational drug No concurrent administration following : `` Magic miracle mouthwash '' contain palliative mixture topical anesthetics/analgesics , coat agent , medication without approved indication topical oral use except liquid antacid formulation ( e.g. , Maalox® Mylanta® generic equivalent ) Other concurrent overthecounter prescription mouthwash beyond systematic oral care protocol provide study drug agent aid oral hygiene ( e.g. , chlorhexidine , gluconate , pilocarpine , amifostine , sucralfate tablet slurry , benzydamine ) Use corticosteroids chronic condition OR within past 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>mucositis</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>recurrent squamous basal cell carcinoma hypopharynx , larynx , lip , nasopharynx</keyword>
	<keyword>oropharynx , paranasal sinus nasal cavity</keyword>
	<keyword>stage I-IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage I-IV lymphoepithelioma oropharynx</keyword>
	<keyword>Recurrent stage I-IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>Recurrent stage I-IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>Recurrent stage I-IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>untreated , current , metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage I verrucous carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage I verrucous carcinoma oral cavity</keyword>
	<keyword>stage II verrucous carcinoma larynx</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage I adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage II adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage I mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage II mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>tongue cancer</keyword>
</DOC>